EP53 – BRAF Mutation in Patients with Bethesda Cytological Indeterminate Thyroid Nodules: After reclassification of a variant thyroid carcinoma

     

    Maneeprasopchoke. P.1; Pongsapich, W.1; Poungvarin, N.2; Amornpichetkul, K.3, Metheetrairut, C.1; Piyawattayakorn, N.1; Vejvisithsakul, P.2; Chongkolwatana, C.1

    1 Department of Otorhinolaryngology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    2 Department of Clinical Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    3 Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

     

    Background: Fine needle aspiration biopsy (FNAB) is widely accepted as a tool for thyroid cancer risk stratification. Atypia of undetermined significant (AUS) and suspicious for malignant cell (SMC) have significant risk for papillary thyroid carcinoma. After the reclassification of a variant thyroid carcinoma, the term “Noninvasive follicular thyroid neoplasm with papillary-like nuclear features” (NIFTP)1 has recently been introduced.

    Objectives:
    To investigate clinical utility of BRAF mutation in Bethesda cytological indeterminate (AUS and SMC) thyroid nodules.

    Methods:
    A Cross-sectional study was conducted in 76 Thai patients with indeterminate nodules from July 2014 to October 2016. Pre-incisional FNAB was performed and sent for BRAFV600 analysis. Mutational status was studied by  direct sequencing and real time PCR techniques. The results were blinded to a pathologist who reviewed the final diagnosis.

    Results:
    BRAFV600 mutation was positive in 13/76 (17.1%) patients with 48.1% sensitivity and 100% specificity for cancer. The malignancy rate was 18.64% in AUS (11/59) with 8 papillary carcinoma, 2 NIFTP, and 1 follicular carcinoma, and 94.2% in SMC (16/17) with 14 papillary thyroid carcinoma and 2 papillary microcarcinoma.
    No BRAF mutation was noted in the NIFTP pathological report, which the patients were treated as papillary microcarcinoma.

    Conclusion:
    Malignancy rate in indeterminate nodule is high. With 100% specificity, BRAF mutation from FNAB has acceptable accuracy that can be part of surgical decision. Following the introduced reclassification, molecular diagnosis could likely be useful for nature of NIFTP.
    References:

    1. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA oncology. 2016

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    June 20 – 22, 2019
    Rome, Italy

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD